COVID-19 therapeutics II: Inhaled antimiR against inflammatory lung damage caused by COVID-19 (CoVmiR) - clinical trial
- Funded by Federal Ministry of Research, Technology and Space (BMFTR)
- Total publications:0 publications
Grant number: 16LW0153
Grant search
Key facts
Disease
COVID-19Start & end year
20212024Known Financial Commitments (USD)
$3,576,252.07Funder
Federal Ministry of Research, Technology and Space (BMFTR)Research Location
GermanyLead Research Institution
LungenClinic Grosshansdorf GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Supportive care, processes of care and managementSpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
UnspecifiedBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified